# EDGAR Filing Document

**Accession Number:** 0001839209
**File Stem:** 0000902664-23-002155
**Filing Date:** 2023-3
**Character Count:** 5650
**Document Hash:** a11bc31bb16c67a31104aed4e6bcf174
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000902664-23-002155.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0000902664-23-002155

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Darwin Global Management, Ltd.
- **CENTRAL INDEX KEY:** 0001839209
- **STATE OF INCORPORATION:** Y9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40505
- **FILM NUMBER:** 23715137

**BUSINESS ADDRESS:**
- **STREET 1:** WHITLEY CHAMBERS
- **STREET 2:** DON STREET
- **CITY:** ST. HELIER
- **STATE:** Y9
- **ZIP:** JE2 4TR
- **BUSINESS PHONE:** (212) 729-7524

**MAIL ADDRESS:**
- **STREET 1:** WHITLEY CHAMBERS
- **STREET 2:** DON STREET
- **CITY:** ST. HELIER
- **STATE:** Y9
- **ZIP:** JE2 4TR
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ambrx Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001836056
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 571147346
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10975 NORTH TORREY PINES ROAD
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** (858) 729-3339

**MAIL ADDRESS:**
- **STREET 1:** 10975 NORTH TORREY PINES ROAD
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Darwin Global Management, Ltd.<br><sub>(Last) (First) (Middle)</sub><br>WHITLEY CHAMBERS<br>DON STREET<br><sub>(Street)</sub><br>ST. HELIER, Y9 JE2 4TR<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Ambrx Biopharma Inc. [ AMAM ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| American Depository Shares ("ADSs")<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 53091423 | $0 | I | See footnotes<sup>(2)(3)</sup> |

---

### Footnotes:

(1) Each ADS represents 7 ordinary shares, par value $0.0001 per share ("Ordinary Shares").

(2) Securities held for the accounts of certain investment funds and accounts for which Darwin Global Management, Ltd. ("Darwin Global") acts as investment manager, including Darwin Global Master Fund, Ltd. ("Master Fund"). The sole shareholder of Darwin Global is controlled by Dr. Abhishek Trehan ("Dr. Trehan").

(3) For purposes of Section 16 of the Securities Exchange Act of 1934, each of Darwin Global, Master Fund and Dr. Trehan expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Darwin Global, Master Fund or Dr. Trehan is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

**Signature:** Darwin Global Management, Ltd. By: /s/ John Legge, Director and Chief Financial Officer  
**Date:** 2023-03-08

**Signature:** /s/ Abhishek Trehan  
**Date:** 2023-03-08

**Signature:** Darwin Global Master Fund, Ltd. By: Darwin Global Management, Ltd, its investment manager By: /s/ John Legge, Director and Chief Financial Officer  
**Date:** 2023-03-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**